• Life and Health Division

  • Important Notice:
    2026 Individual Qualified Health Plan and Small Group Plan Rates

    Please see for details

The Life and Health Division reviews all health and life insurance contracts (policies), rates, advertisements and other forms for compliance with all applicable laws and regulations. We must approve all of these prior to the marketing of the insurance product. The Division also ensures that commercial health insurers comply with laws and regulations concerning the adequacy of provider networks, utilization management policies and prior authorization processes, member and provider grievance practices, quality improvement plans, cultural competency training, and behavioral health parity laws. 

In addition, the Life and Health Division oversees prescription benefit managers’ (PBMs) compliance with laws and regulations, and we administer aspects of the Vaccine Purchasing Act (VPA) in cooperation with the New Mexico Department of Health. The Division also supports OSI’s goal of increasing access to affordable health insurance coverage through policy innovation, the implementation of legislative initiatives, and ongoing economic and demographic research concerning health insurance coverage and affordability.

Recent News

Get the latest information about rule changes, legislation, industry information and consumer news.

Read All OSI News

MEDICAL MALPRACTICE PREMIUM REDUCTION

AMENDED BULLETIN 2026-010: The New Mexico State Legislature appropriated $5 million to the New Mexico Office of Superintendent of Insurance (OSI) to address medical malpractice insurance costs for individual providers. The appropriation was part of a supplemental appropriation package passed in 2025. This one-time appropriation directs OSI to provide a premium subsidy for private medical malpractice insurance policies. […]

Read More

NOTICE OF PRESCRIPTION DRUG PRICE TRANSPARENCY ANNUAL MEETING

The Office of the Superintendent of Insurance will hold its annual public meeting to present and discuss the findings and recommendations contained in the 2025 Prescription Drug Price Transparency legislative report. The purpose of this meeting is to inform the public of the report’s contents and to provide an opportunity for public comments and questions. […]

Read More